GSK, Pfizer and RSV
Shares of GSK PLC GSK rose 1.40% to £14.80 Monday, on what proved to be an all-around favorable trading session for the stock ...
Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.50.
GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | ...
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...
After several high-profile failures, including BMS’ $1.5B breakup with Agenus, anti-TIGIT therapies are generating cautious ...
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...
GSK Plc CEO Emma Walmsley doesn’t want the company’s employees spending any time thinking about the ongoing litigation over ...
GSK PLC GSK shares inched down 0.07% to £14.60 Friday, on what proved to be an all-around dismal trading session for the stock market, with the FTSE 100 Index UKX falling 0.02% to 8,280.63. Supported ...
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...
GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, ...
GSK's ViiV Healthcare has suspended development of a Phase 2-stage HIV antiviral named VH3739937, a GSK spokesperson ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback